Case series of low dose rituximab for membranous nephropathy; a single centre experience

• Hauptverfasser: Gerry George Mathew (Verfasst von), Jayaprakash Varadharajan (Verfasst von), Sreedhar Sailapathy (Verfasst von)
• Format: Buch
• Veröffentlicht: Society of Diabetic Nephropathy Prevention, 2023-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Introduction: Rituximab is the recent treatment of choice for primary membranous nephropathy However, dose of rituximab mentioned in literature is high and not economical in middle income countries. Low dose rituximab based on CD 19 cell count can be tried as an alternative for high dose rituximab f...